Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 9/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21531212 | 0.92 | MAPT (0.52) | MAPTKDM4EALDH1A1POLBFOLH1 | |
| SCHEMBL21553600 | 0.91 | MAPT (0.54) | MAPTKDM4EALDH1A1POLBFOLH1 | |
| SCHEMBL23153703 | 0.87 | MAPT (0.60) | MAPTKDM4EALDH1A1POLBFOLH1 | |
| SCHEMBL16172122 | 0.85 | ALDH1A1 (0.52) | MAPTKDM4EALDH1A1POLBFOLH1 | |
| SCHEMBL21531189 | 0.84 | MAPT (0.48) | MAPTKDM4EALDH1A1POLBFOLH1 | |
| SCHEMBL21531191 | 0.84 | MAPT (0.48) | MAPTKDM4EALDH1A1POLBFOLH1 | |
| SCHEMBL4427988 | 0.83 | MAPT (0.57) | MAPTKDM4EALDH1A1POLBFOLH1 | |
| SCHEMBL31481345 | 0.83 | MAPT (0.57) | MAPTKDM4EALDH1A1POLBFOLH1 | |
| SCHEMBL21531127 | 0.83 | KMT2A (0.60) | MAPTKDM4EALDH1A1POLBFOLH1 | |
| SCHEMBL23705002 | 0.82 | MAPT (0.49) | MAPTKDM4EALDH1A1POLBFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-12-09 | — | — | US | disclosed |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | MAPT 3689/4885KDM4E 4738/4885ALDH1A1 4695/4885 |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | MAPT 3357/4885KDM4E 4771/4885ALDH1A1 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.